PubMed
RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia
Miyamoto H, Yeh S, Lardy H, et al. J Steroid Biochem Mol Biol. 1997
Skin & AestheticsResearch OnlyC
RU-58841
RU58841
Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).
Last reviewed . First published . By the PeptIQ team.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 100
- Activity
- 74
Overall check-ins
Trackers & reports
Overview
About RU-58841
Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).
- Category
- Skin & Aesthetics
- Regulatory status
- Research Only
- Also known as
- RU58841
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
6
Mood
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Sources (3)
- Wiki study page →Source
- Wiki study page →Source
PubMed
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques
Pan HJ, Wilding G, Uno H, et al. Endocrine. 1998
- Wiki study page →Source
PubMed
Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats
Ye F, Imamura K, Imanishi N, et al. Skin pharmacology : the official journal of the Skin Pharmacology Society. 1997
Tools
Explore more
Explore
More ways to learn about RU-58841 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about RU-58841?
This page summarizes 6 anonymized self-reports from PeptIQ users who track RU-58841, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for RU-58841?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for RU-58841?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is RU-58841 safe to use?
This wiki does not assess safety or recommend use. RU-58841 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of RU-58841?
This wiki summarizes observational community reports and linked citations for RU-58841. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for RU-58841 for study-level context — not medical advice.
What is the legal status of RU-58841?
RU-58841 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of RU-58841?
Safety data quality for RU-58841 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on RU-58841?
This page links 3 sources for RU-58841. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.